ReviewPathologica2022
Prostate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors?
Review in Pathologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Generalizability of a biopsy-trained artificial intelligence algorithm to TURP and HoLEP specimens for detection of incidental prostate adenocarcinoma.Diagnostic pathology · 2026Article
- Article
- AI-Driven Drug Discovery: Focus on Targets for Solid Tumors.Pharmaceutics · 2026Review
- TRPML1 inhibitor ML-SI1 suppresses prostate cancer through dual regulation of androgen receptor and polyamine metabolism.Frontiers in medicine · 2026Article
- Metastatic Small Cell Neuroendocrine Carcinoma of the Prostate: A Rare and Aggressive Case Report From Bangladesh.Case reports in oncological medicine · 2026Article
- Comparing the outcomes of ductal versus acinar adenocarcinoma in patients undergoing robotic-assisted radical prostatectomy: propensity-matched analysis of a prostate cancer referral center.International urology and nephrology · 2026Article
- Intraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies.Histology and histopathology · 2025Review
- Review
- Severe and enduring prostate cancer burden attributable to smoking among old men amid global decline and socioeconomic disparities.Scientific reports · 2025Article
- Secondary Prostate Lymphoma Mimicking Prostate Cancer Successfully Managed by Transurethral Resection to Relieve Urinary Retention.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Secondary signet ring cell carcinoma of the prostate: a case report.Journal of surgical case reports · 2025Article
- Omics Investigations of Prostate Cancer Cells Exposed to Simulated Microgravity Conditions.Biomolecules · 2025Article
- Review
- Signet-ring cell carcinoma in rectal malignancies: a case report with an unexpected outcome.Frontiers in oncology · 2025Article
- Solitary testicular metastasis post-prostatectomy for prostatic ductal adenocarcinoma: case report and literature review.Frontiers in oncology · 2025Article
- Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects.Asian journal of andrology · 2024Review
- Application and new findings of scRNA-seq and ST-seq in prostate cancer.Cell regeneration (London, England) · 2024Review
- Metastatic prostate adenocarcinoma to the brain - a clinicopathologic analysis of 21 cases.Diagnostic pathology · 2024Article
- Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy.Scientific reports · 2024Article
- Dual immunotherapy alternating with anti-PD-1 antibody plus liposomal doxorubicin show good efficacy in prostate epithelioid hemangioendothelioma: a case report.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2022, after a six-year interval, the International Agency for Research on Cancer (IARC) has published the 5th edition of the WHO Classification of Urinary and Male Genital Tumors, which provides a comprehensive update on tumor classification of the genitourinary system. This review article focuses on prostate carcinoma and underscores changes in the prostate chapter as well as those made across the entire series of the 5th edition of WHO Blue Books. Although no major alterations were made to this chapter, some of the most notable updates include restructure of contents and introduction of a new format; standardization of mitotic counts, genomic nomenclatures, and units of length; refined definition for the terms "variant", "subtype", and "histologic pattern"; reclassification of prostatic intraepithelial neoplasia (PIN)-like adenocarcinoma as a subtype of prostatic acinar adenocarcinoma; and recognition of treatment-related neuroendocrine prostatic carcinoma as a distinct tumor type. Evolving and unsettled issues related to grading of intraductal carcinoma of the prostate and reporting of tertiary Gleason pattern, the definition and prognostic significance of cribriform growth pattern, and molecular pathology of prostate cancer will also be covered in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.